Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Acadia Pharmaceutica
(NQ:
ACAD
)
17.00
-0.05 (-0.29%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Acadia Pharmaceutica
< Previous
1
2
3
4
5
6
Next >
Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
December 22, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)
December 20, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer
December 14, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
December 06, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia
December 01, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly – a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinson’s Disease Non-Motor Symptoms
November 16, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results
November 08, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021
November 02, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial
November 01, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021
October 27, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson’s Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 25, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
September 02, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Executive Leadership Change
September 01, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Long Term Investor Notice: Investigation of Potential Wrongdoing
August 25, 2021
San Diego, CA -- (SBWIRE) -- 08/25/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of ACADIA Pharmaceuticals Inc.
Via
SBWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021
August 05, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results
August 04, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis
July 21, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Second Quarter 2021 Financial Results on August 4, 2021
July 21, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer’s Association International Conference 2021 (AAIC)
July 14, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
June 21, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
June 20, 2021
From
The Schall Law Firm
Via
Business Wire
MONDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
June 19, 2021
From
The Schall Law Firm
Via
Business Wire
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
June 18, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
June 17, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Acadia Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
June 16, 2021
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)
June 16, 2021
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Two Days Left to Actively Participate in ACADIA Pharmaceuticals Inc. (ACAD) Class Action: Bronstein, Gewirtz & Grossman, LLC
June 16, 2021
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
FRIDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
June 16, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
FRIDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
June 15, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
FRIDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
June 14, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.